{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:40Z","timestamp":1792686100189,"version":"4.5.0"},"reference-count":145,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,4,24]]},"DOI":"10.1253\/circj.cj-19-0705","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T22:04:05Z","timestamp":1582668245000},"page":"685-694","source":"Crossref","is-referenced-by-count":105,"title":["Cardiac Arrhythmias in Autoimmune Diseases"],"prefix":"10.1253","volume":"84","author":[{"given":"Monika","family":"Gawa\u0142ko","sequence":"first","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Balsam","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Lodzi\u0144ski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Krzowski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u0119drzej","family":"Kosiuk","sequence":"additional","affiliation":[{"name":"1st Chair and Department of Cardiology, Medical University of Warsaw"},{"name":"Department of Electrophysiology, Helios Klinikum Koethen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. \u2002Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing. <i>Int J Celiac Dis<\/i> 2015; 3: 151\u2013155.","DOI":"10.12691\/ijcd-3-4-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. \u2002Seferovic PM, Ristic AD, Maksimovic R, Simeunovic DS, Ristic GG, Radovanovic G, et al. Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases. <i>Rheumatology<\/i> 2006; 45: iv39\u2013iv42.","DOI":"10.1093\/rheumatology\/kel315"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. \u2002Arkema EV, Cozier YC. Epidemiology of sarcoidosis: Current findings and future directions. <i>Ther Adv Chronic Dis<\/i> 2018; 9: 227\u2013240.","DOI":"10.1177\/2040622318790197"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. \u2002Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: Its mechanisms and outcome. <i>Clin Cardiol<\/i> 2004; 27: 217\u2013222.","DOI":"10.1002\/clc.4960270409"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. \u2002Salama A, Abdullah A, Wahab A, Eigbire G, Hoefen R, Alweis R. Cardiac sarcoidosis and ventricular arrhythmias. A rare association of a rare disease. A retrospective cohort study from the National Inpatient Sample and current evidence for management.  <i>Cardiol J<\/i>, doi:10.5603\/CJ.a2018.0104.","DOI":"10.5603\/CJ.a2018.0104"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. \u2002Viles-Gonzalez JF, Pastori L, Fischer A, Wisnivesky JP, Goldman MG, Mehta D. Supraventricular arrhythmias in patients with cardiac sarcoidosis prevalence, predictors, and clinical implications. <i>Chest<\/i> 2013; 143: 1085\u20131090.","DOI":"10.1378\/chest.11-3214"},{"key":"7","unstructured":"7. \u2002Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis: Diagnosis and management. <i>Eur Heart J<\/i> 2017; 38: 2663\u20132670."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. \u2002Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: A comprehensive review. <i>Arch Med Sci<\/i> 2011; 7: 546\u2013554.","DOI":"10.5114\/aoms.2011.24118"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. \u2002Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. <i>Ann Noninvasive Electrocardiol<\/i> 2011; 16: 140\u2013147.","DOI":"10.1111\/j.1542-474X.2011.00418.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. \u2002Winters SL, Cohen M, Greenberg S, Stein B, Curwin J, Pe E, et al. Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. <i>J Am Coll Cardiol<\/i> 1991; 18: 937\u2013943.","DOI":"10.1016\/0735-1097(91)90750-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. \u2002Kopriva P, Griva M, T\u00fcd\u00f6s Z. Management of cardiac sarcoidosis: A practical guide. <i>Cor et Vasa<\/i> 2018; 60: e155\u2013e164.","DOI":"10.1016\/j.crvasa.2017.05.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. \u2002Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. <i>N Engl J Med<\/i> 1991; 324: 781\u2013788.","DOI":"10.1056\/NEJM199103213241201"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. \u2002Doughan AR, Williams BR. Cardiac sarcoidosis. <i>Heart<\/i> 2006; 92: 282\u2013288.","DOI":"10.1136\/hrt.2005.080481"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. \u2002Papageorgiou N, Provid\u00eancia R, Bronis K, Dechering DG, Srinivasan N, Eckardt L, et al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoidosis: A systematic review. <i>Europace<\/i> 2018; 20: 682\u2013691.","DOI":"10.1093\/europace\/eux077"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. \u2002Muser D, Liang JJ, Pathak RK, Magnani S, Castro SA, Hayashi T, et al. Long-term outcomes of catheter ablation of ventricular tachycardia in patients with cardiac sarcoidosis. <i>Circ Arrhythm Electrophysiol<\/i> 2016; 9: pii: e004333.","DOI":"10.1161\/CIRCEP.116.004333"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. \u2002Bogun FM, Desjardins B, Good E, Gupta S, Crawford T, Oral H, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: Utility for identifying the ventricular arrhythmia substrate. <i>J Am Coll Cardiol<\/i> 2009; 53: 1138\u20131145.","DOI":"10.1016\/j.jacc.2008.11.052"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. \u2002Willner JM, Viles-Gonzalez JF, Coffey JO, Morgenthau AS, Mehta D. Catheter ablation of atrial arrhythmias in cardiac sarcoidosis. <i>J Cardiovasc Electrophysiol<\/i> 2014; 25: 958\u2013963.","DOI":"10.1111\/jce.12424"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. \u2002Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. <i>Rheumatology (Oxford)<\/i> 2017; 56: 1945\u20131961.","DOI":"10.1093\/rheumatology\/kex260"},{"key":"19","unstructured":"19. \u2002Teixeira RA, Borba EF, Bonf\u00e1 E, Martinelli Filho M. Arrhythmias in systemic lupus erythematosus. <i>Rev Bras Reumatol<\/i> 2010; 50: 81\u201389."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. \u2002Bourr\u00e9-Tessier J, Clarke AE, Huynh T, Bernatsky S, Joseph L, Belisle P, et al. Prolonged corrected QT interval in anti-Ro\/SSA-positive adults with systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)<\/i> 2011; 63: 1031\u20131037.","DOI":"10.1002\/acr.20470"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. \u2002Ashrafi R, Garg P, McKay E, Gosney J, Chuah S, Davis G. Aggressive cardiac involvement in systemic lupus erythematosus: A case report and a comprehensive literature review. <i>Cardiol Res Pract<\/i> 2011; 2011: 578390.","DOI":"10.4061\/2011\/578390"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. \u2002Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G, et al. Prolongation of the corrected QT interval in adult patients with anti-Ro\/SSA-positive connective tissue diseases. <i>Arthritis Rheum<\/i> 2004; 50: 1248\u20131252.","DOI":"10.1002\/art.20130"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. \u2002Santos-Pardo I, Villuendas R, Salvador-Corres I, Mart\u00ednez-Morillo M, Oliv\u00e9 A, Bayes-Genis A. Anti-Ro\/SSA antibodies and cardiac rhythm disturbances: Present and future perspectives. <i>Int J Cardiol<\/i> 2015; 184: 244\u2013250.","DOI":"10.1016\/j.ijcard.2014.11.002"},{"key":"24","unstructured":"24. \u2002Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, et al. Autoantibodies associated with connective tissue diseases: What meaning for clinicians? <i>Front Immunol<\/i> 2018; 9: 541."},{"key":"25","unstructured":"25. \u2002Romano C, Sirotti V, Farinaro V, Luiso V, Solaro E, De Sio C, et al. Atrial fibrillation following therapy with high-dose i.v. methylprednisolone: A brief case-based review. <i>Eur J Rheumatol<\/i> 2017; 4: 231\u2013233."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. \u2002Barnado A, Carroll RJ, Casey C, Wheless L, Denny JC, Crofford LJ. Phenome-wide association studies uncover a novel association of increased atrial fibrillation in male patients with systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)<\/i> 2018; 70: 1630\u20131636.","DOI":"10.1002\/acr.23553"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. \u2002Salem JE, Alexandre J, Bachelot A, Funck-Brentano C. Influence of steroid hormones on ventricular repolariza-tion. <i>Pharmacol Ther<\/i> 2016; 167: 38\u201347.","DOI":"10.1016\/j.pharmthera.2016.07.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. \u2002Morgan ND, Patel SV, Dvorkina O. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. <i>J Clin Rheumatol<\/i> 2013; 19: 286\u2013288.","DOI":"10.1097\/RHU.0b013e31829d5e50"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. \u2002Wozniacka A, Cygankiewicz I, Chudzik M, Sysa-Jedrzejowska A, Wranicz JK. The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: The influence on arrhythmia, heart rate variability and repolarization parameters. <i>Lupus<\/i> 2006; 15: 521\u2013525.","DOI":"10.1191\/0961203306lu2345oa"},{"key":"30","unstructured":"30. \u2002McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. <i>Clin Exp Rheumatol<\/i> 2018; 36: 545\u2013551."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. \u2002Noujaim SF, Stuckey JA, Ponce-Balbuena D, Ferrer-Villada T, L\u00f3pez-Izquierdo A, Pandit SV, et al. Structural bases for the different anti-fibrillatory effects of chloroquine and quinidine. <i>Cardiovasc Res<\/i> 2011; 89: 862\u2013869.","DOI":"10.1093\/cvr\/cvr008"},{"key":"32","unstructured":"32. \u2002US Food and Drug Administration (FDA). https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (accessed November 1, 2019)."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. \u2002dal Piaz EC, Casagranda G, Ravanelli D, Marini M, Valentini A, Del Greco M. Extensive atrial fibrosis in a patient with systemic lupus erythematosus and atrial fibrillation. <i>HeartRhythm Case Rep<\/i> 2015; 1: 206\u2013208.","DOI":"10.1016\/j.hrcr.2015.02.014"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. \u2002Barnes J, Mayes MD. Epidemiology of systemic sclerosis: Incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. <i>Curr Opin Rheumatol<\/i> 2012; 24: 165\u2013170.","DOI":"10.1097\/BOR.0b013e32834ff2e8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36. \u2002Borowiec A, Dabrowski R, Wozniak J, Jasek S, Chwyczko T, Kowalik I, et al. Cardiovascular assessment of asymptomatic patients with juvenile-onset localized and systemic scleroderma: 10 years prospective observation. <i>Scand J Rheumatol<\/i> 2012; 41: 33\u201338.","DOI":"10.3109\/03009742.2011.609489"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37. \u2002Kostis JB, Seibold JR, Turkevich D, Masi AT, Grau RG, Medsger TA Jr, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. <i>Am J Med<\/i> 1988; 84: 1007\u20131015.","DOI":"10.1016\/0002-9343(88)90305-1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38. \u2002Wozniak J, Dabrowski R, Luczak D, Kwiatkowska M, Musiej-Nowakowska E, Kowalik I, et al. Evaluation of heart rhythm variability and arrhythmia in children with systemic and localized scleroderma. <i>J Rheumatol<\/i> 2009; 36: 191\u2013196.","DOI":"10.3899\/jrheum.080021"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39. \u2002Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR scleroderma trial and research group (EUSTAR) database of patients with systemic sclerosis. <i>Ann Rheum Dis<\/i> 2010; 69: 218\u2013221.","DOI":"10.1136\/ard.2008.103382"},{"key":"39","unstructured":"40. \u2002Gialafos E, Konstantopoulou P, Voulgari C, Giavri I, Panopoulos S, Vaiopoulos G, et al. Abnormal spatial QRS-T angle, a marker of ventricular repolarisation, predicts serious ventricular arrhythmia in systemic sclerosis. <i>Clin Exp Rheumatol<\/i> 2012; 30: 327\u2013331."},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. \u2002Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: A cause of cardiac dysfunction. <i>Circulation<\/i> 1976; 53: 483\u2013490.","DOI":"10.1161\/01.CIR.53.3.483"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. \u2002Brisinda D, Sorbo AR, Venuti A, Ruggieri MP, Manna R, Fenici P, et al. Anti-\u03b2-adrenoceptors autoimmunity causing \u2018idiopathic\u2019 arrhythmias and cardiomyopathy. <i>Circ J<\/i> 2012; 76: 1345\u20131353.","DOI":"10.1253\/circj.CJ-11-1374"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43. \u2002Cozzolino D, Naclerio C, Iengo R, D\u2019Angelo S, Cuomo G, Valentini G. Cardiac autonomic dysfunction precedes the development of fibrosis in patients with systemic sclerosis. <i>Rheumatology (Oxford)<\/i> 2002; 41: 586\u2013588.","DOI":"10.1093\/rheumatology\/41.5.586"},{"key":"43","unstructured":"44. \u2002Muresan L, Petcu A, Pamfil C, Muresan C, Rinzis M, Mada RO, et al. Cardiovascular profiles of scleroderma patients with arrhythmias and conduction disorders. <i>Acta Reumatol Port<\/i> 2016; 41: 26\u201339."},{"key":"44","doi-asserted-by":"crossref","unstructured":"45. \u2002Follansbee WP, Zerbe TR, Medsger TA Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): A high risk association. <i>Am Heart J<\/i> 1993; 125: 194\u2013203.","DOI":"10.1016\/0002-8703(93)90075-K"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46. \u2002Bernardo P, Conforti ML, Bellando-Randone S, Pieragnoli P, Blagojevic J, Kaloudi O, et al. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis. <i>J Rheumatol<\/i> 2011; 38: 1617\u20131621.","DOI":"10.3899\/jrheum.100480"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47. \u2002De Luca G, Bosello S, Leone AM, Gabrielli F, Pelargonio G, Inzani F, et al. Life-threatening arrhythmias in a scleroderma patient: The role of myocardial inflammation in arrhythmic outburst. <i>Scand J Rheumatol<\/i> 2017; 46: 78\u201380.","DOI":"10.3109\/03009742.2016.1157626"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48. \u2002Chung HH, Kim JB, Hong SH, Lee HJ, Joung B, Lee MH. Radiofrequency catheter ablation of hemodynamically unstable ventricular tachycardia associated with systemic sclerosis. <i>J Korean Med Sci<\/i> 2012; 27: 215\u2013217.","DOI":"10.3346\/jkms.2012.27.2.215"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49. \u2002Chatzidou S, Repasos V, Palios J, Plastiras S. Usefulness of cardiovascular magnetic resonance imaging in supraventricular tachycardia ablation in a scleroderma patient. <i>Hellenic J Cardiol<\/i> 2017; 58: 159\u2013160.","DOI":"10.1016\/j.hjc.2016.10.006"},{"key":"49","unstructured":"50. \u2002Frese T, Sandholzer H. The epidemiology of type 1 diabetes mellitus. <i>In<\/i>: Escher A, Li A, editors. Type 1 diabetes. IntechOpen. 2013. https:\/\/www.intechopen.com\/books\/type-1-diabetes\/the-epidemiology-of-type-1-diabetes-mellitus (accessed November 1, 2019)."},{"key":"50","doi-asserted-by":"crossref","unstructured":"51. \u2002Dahlqvist S, Rosengren A, Gudbj\u00f6rnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: A prospective case-control study. <i>Lancet Diabetes Endocrinol<\/i> 2017; 5: 799\u2013807.","DOI":"10.1016\/S2213-8587(17)30262-0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52. \u2002Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: Results of a long-term follow-up prospective study. <i>J Diabetes Complications<\/i> 2003; 17: 169\u2013178.","DOI":"10.1016\/S1056-8727(02)00206-4"},{"key":"52","doi-asserted-by":"crossref","unstructured":"54. \u2002Zhang Q, Liu T, Ng CY, Li G. Diabetes mellitus and atrial remodeling: Mechanisms and potential upstream therapies. <i>Cardiovasc Ther<\/i> 2014; 32: 233\u2013241.","DOI":"10.1111\/1755-5922.12089"},{"key":"53","doi-asserted-by":"crossref","unstructured":"55. \u2002Fu H, Li G, Liu C, Li J, Cheng L, Yang W, et al. Probucol prevents atrial remodeling by inhibiting oxidative stress and TNF-\u03b1\/NF-\u03baB\/TGF-\u03b2 signal transduction pathway in alloxan-induced diabetic rabbits. <i>J Cardiovasc Electrophysiol<\/i> 2015; 26: 211\u2013222.","DOI":"10.1111\/jce.12540"},{"key":"54","doi-asserted-by":"crossref","unstructured":"56. \u2002Yaras N, Turan B. Interpretation of relevance of sodium-calcium exchange in action potential of diabetic rat heart by mathematical model. <i>Mol Cell Biochem<\/i> 2005; 269: 121\u2013129.","DOI":"10.1007\/s11010-005-3439-8"},{"key":"55","doi-asserted-by":"crossref","unstructured":"57. \u2002Kato T, Yamashita T, Sekiguchi A, Tsuneda T, Sagara K, Takamura M, et al. AGEs-RAGE system mediates atrial structural remodeling in the diabetic rat. <i>J Cardiovasc Electrophysiol<\/i> 2008; 19: 415\u2013420.","DOI":"10.1111\/j.1540-8167.2007.01037.x"},{"key":"56","doi-asserted-by":"crossref","unstructured":"58. \u2002Chen J, Li Q, Dong R, Gao H, Peng H, Wu Y. The effect of the Ras homolog gene family (Rho), member A\/Rho associated coiled-coil forming protein kinase pathway in atrial fibrosis of type 2 diabetes in rats. <i>Exp Ther Med<\/i> 2014; 8: 836\u2013840.","DOI":"10.3892\/etm.2014.1843"},{"key":"57","doi-asserted-by":"crossref","unstructured":"59. \u2002Chen X, Bing Z, He J, Jiang L, Luo X, Su Y, et al. Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation. <i>Clin Cardiol<\/i> 2009; 32: 337\u2013345.","DOI":"10.1002\/clc.20566"},{"key":"58","doi-asserted-by":"crossref","unstructured":"60. \u2002Scridon A, Fouilloux-Meugnier E, Loizon E, Rome S, Julien C, Barr\u00e8s C, et al. Long-standing arterial hypertension is associated with Pitx2 down-regulation in a rat model of spontaneous atrial tachyarrhythmias. <i>Europace<\/i> 2015; 17: 160\u2013165.","DOI":"10.1093\/europace\/euu139"},{"key":"59","doi-asserted-by":"crossref","unstructured":"61. \u2002Shimabukuro M, Higa N, Asahi T, Yamakawa K, Oshiro Y, Higa M, et al. Impaired glucose tolerance, but not impaired fasting glucose, underlies left ventricular diastolic dysfunction. <i>Diabetes Care<\/i> 2011; 34: 686\u2013690.","DOI":"10.2337\/dc10-1141"},{"key":"60","doi-asserted-by":"crossref","unstructured":"63. \u2002Linz D, Hohl M, Dhein S, Ruf S, Reil JC, Kabiri M, et al. Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. <i>Cardiovasc Res<\/i> 2016; 110: 371\u2013380.","DOI":"10.1093\/cvr\/cvw071"},{"key":"61","doi-asserted-by":"crossref","unstructured":"64. \u2002Otake H, Suzuki H, Honda T, Maruyama Y. Influences of autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. <i>Int Heart J<\/i> 2009; 50: 627\u2013641.","DOI":"10.1536\/ihj.50.627"},{"key":"62","doi-asserted-by":"crossref","unstructured":"65. \u2002Pistrosch F, Ganz X, Bornstein SR, Birkenfeld AL, Henkel E, Hanefeld M. Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: A cohort study under real-world conditions. <i>Acta Diabetol<\/i> 2015; 52: 889\u2013895.","DOI":"10.1007\/s00592-015-0727-y"},{"key":"63","doi-asserted-by":"crossref","unstructured":"66. \u2002Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). <i>Am J Cardiol<\/i> 2014; 114: 1217\u20131222.","DOI":"10.1016\/j.amjcard.2014.07.045"},{"key":"64","doi-asserted-by":"crossref","unstructured":"67. \u2002Chang SH, Wu LS, Chiou MJ, Liu JR, Yu KH, Kuo CF, et al. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: A population-based dynamic cohort and in vitro studies. <i>Cardiovasc Diabetol<\/i> 2014; 13: 123.","DOI":"10.1186\/s12933-014-0123-x"},{"key":"65","doi-asserted-by":"crossref","unstructured":"68. \u2002Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2. <i>Europace<\/i> 2011; 13: 1256\u20131261.","DOI":"10.1093\/europace\/eur131"},{"key":"66","doi-asserted-by":"crossref","unstructured":"69. \u2002Chao TF, Leu HB, Huang CC, Chen JW, Chan WL, Lin SJ, et al. Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. <i>Int J Cardiol<\/i> 2012; 156: 199\u2013202.","DOI":"10.1016\/j.ijcard.2011.08.081"},{"key":"67","doi-asserted-by":"crossref","unstructured":"70. \u2002Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: Results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. <i>J Cardiovasc Electrophysiol<\/i> 2009; 20: 22\u201328.","DOI":"10.1111\/j.1540-8167.2008.01275.x"},{"key":"68","doi-asserted-by":"crossref","unstructured":"71. \u2002Tang RB, Dong JZ, Liu XP, Fang DP, Long DY, Liu XH, et al. Safety and efficacy of catheter ablation of atrial fibrillation in patients with diabetes mellitus: Single center experience. <i>J Interv Card Electrophysiol<\/i> 2006; 17: 41\u201346.","DOI":"10.1007\/s10840-006-9049-x"},{"key":"69","doi-asserted-by":"crossref","unstructured":"72. \u2002Kosiuk J, Dinov B, Kornej J, Acou WJ, Sch\u00f6nbauer R, Fiedler L, et al. Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score. <i>Heart Rhythm<\/i> 2015; 12: 2207\u20132212.","DOI":"10.1016\/j.hrthm.2015.07.003"},{"key":"70","doi-asserted-by":"crossref","unstructured":"73. \u2002Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. <i>Autoimmun Rev<\/i> 2003; 2: 119\u2013125.","DOI":"10.1016\/S1568-9972(03)00006-5"},{"key":"71","doi-asserted-by":"crossref","unstructured":"74. \u2002Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. <i>Thyroid<\/i> 2002; 12: 489\u2013493.","DOI":"10.1089\/105072502760143863"},{"key":"72","doi-asserted-by":"crossref","unstructured":"75. \u2002Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. <i>N Engl J Med<\/i> 1994; 331: 1249\u20131252.","DOI":"10.1056\/NEJM199411103311901"},{"key":"73","doi-asserted-by":"crossref","unstructured":"76. \u2002Kobayashi H, Haketa A, Abe M, Tahira K, Hatanaka Y, Tanaka S, et al. Unusual manifestation of Graves\u2019 disease: Ventricular fibrillation. <i>Eur Thyroid J<\/i> 2015; 4: 207\u2013212.","DOI":"10.1159\/000437225"},{"key":"74","doi-asserted-by":"crossref","unstructured":"77. \u2002Chen YC, Chen SA, Chen YJ, Chang MS, Chan P, Lin CI. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. <i>J Am Coll Cardiol<\/i> 2002; 39: 366\u2013372.","DOI":"10.1016\/S0735-1097(01)01731-4"},{"key":"75","doi-asserted-by":"crossref","unstructured":"78. \u2002Watanabe H, Ma M, Washizuka T, Komura S, Yoshida T, Hosaka Y, et al. Thyroid hormone regulates mRNA expression and currents of ion channels in rat atrium. <i>Biochem Biophys Res Commun<\/i> 2003; 308: 439\u2013444.","DOI":"10.1016\/S0006-291X(03)01420-7"},{"key":"76","doi-asserted-by":"crossref","unstructured":"79. \u2002Jia G, Sowers JR. Autoantibodies of \u03b2-adrenergic and M<sub>2<\/sub> cholinergic receptors: Atrial fibrillation in hyperthyroidism. <i>Endocrine<\/i> 2015; 49: 301\u2013303.","DOI":"10.1007\/s12020-015-0556-3"},{"key":"77","doi-asserted-by":"crossref","unstructured":"80. \u2002Reddy V, Taha W, Kundumadam S, Khan M. Atrial fibrillation and hyperthyroidism: A literature review. <i>Indian Heart J<\/i> 2017; 69: 545\u2013550.","DOI":"10.1016\/j.ihj.2017.07.004"},{"key":"78","doi-asserted-by":"crossref","unstructured":"82. \u2002Scott GR, Forfar JC, Toft AD. Graves\u2019 disease and atrial fibrillation: The case for even higher doses of therapeutic iodine-131. <i>Br Med J (Clin Res Ed)<\/i> 1984; 289: 399\u2013400.","DOI":"10.1136\/bmj.289.6442.399"},{"key":"79","doi-asserted-by":"crossref","unstructured":"83. \u2002Gauthier JM, Mohamed HE, Noureldine SI, Nazari-Shafti TZ, Thethi TK, Kandil E. Impact of thyroidectomy on cardiac manifestations of Graves\u2019 disease. <i>Laryngoscope<\/i> 2016; 126: 1256\u20131259.","DOI":"10.1002\/lary.25687"},{"key":"80","unstructured":"84. \u2002Kunii Y, Uruno T, Matsumoto M, Mukasa K, Noh J, Ito K, et al. Pharmacological conversion of atrial fibrillation in the patients of Graves\u2019 disease. <i>Tokai J Exp Clin Med<\/i> 2012; 37: 107\u2013112."},{"key":"81","unstructured":"85. \u2002Wei H, Li M, Qiu M. Treatment of hyperthyroid atrial fibrillation associated with Graves disease by prednisone. <i>Zhonghua Yi Xue Za Zhi<\/i> 2002; 82: 810\u2013812 (in Chinese)."},{"key":"82","doi-asserted-by":"crossref","unstructured":"86. \u2002Ma CS, Liu X, Hu FL, Dong JZ, Liu XP, Wang XH, et al. Catheter ablation of atrial fibrillation in patients with hyperthyroidism. <i>J Interv Card Electrophysiol<\/i> 2007; 18: 137\u2013142.","DOI":"10.1007\/s10840-007-9088-y"},{"key":"83","doi-asserted-by":"crossref","unstructured":"87. \u2002Wongcharoen W, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, et al. History of hyperthyroidism and long-term outcome of catheter ablation of drug-refractory atrial fibrillation. <i>Heart Rhythm<\/i> 2015; 12: 1956\u20131962.","DOI":"10.1016\/j.hrthm.2015.06.004"},{"key":"84","doi-asserted-by":"crossref","unstructured":"88. \u2002Horacek J, Maly J, Svilias I, Smolej L, Cepkova J, Vizda J, et al. Prothrombotic changes due to an increase in thyroid hormone levels. <i>Eur J Endocrinol<\/i> 2015; 172: 537\u2013542.","DOI":"10.1530\/EJE-14-0801"},{"key":"85","doi-asserted-by":"crossref","unstructured":"89. \u2002Hansten PD. Oral anticoagulants and drugs which alter thyroid function. <i>Drug Intelligence Clin Pharm<\/i> 1980; 14: 331\u2013334.","DOI":"10.1177\/106002808001400502"},{"key":"86","doi-asserted-by":"crossref","unstructured":"90. \u2002Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. <i>Semin Arthritis Rheum<\/i> 2006; 36: 182\u2013188.","DOI":"10.1016\/j.semarthrit.2006.08.006"},{"key":"87","doi-asserted-by":"crossref","unstructured":"91. \u2002Bacani AK, Crowson CS, Roger VL, Gabriel SE, Matteson EL. Increased incidence of atrial fibrillation in patients with rheumatoid arthritis. <i>Biomed Res Int<\/i> 2015; 2015: 809514.","DOI":"10.1155\/2015\/809514"},{"key":"88","doi-asserted-by":"crossref","unstructured":"92. \u2002Pizzuto K, Averns HL, Baranchuk A, Abdollah H, Michael KA, Simpson C, et al. Celecoxib-induced change in atrial electrophysiologic substrate in arthritis patients. <i>Ann Noninvasive Electrocardiol<\/i> 2014; 1: 50\u201356.","DOI":"10.1111\/anec.12097"},{"key":"89","doi-asserted-by":"crossref","unstructured":"94. \u2002Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, et al. Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. <i>BMJ<\/i> 2012; 344: e1257.","DOI":"10.1136\/bmj.e1257"},{"key":"90","doi-asserted-by":"crossref","unstructured":"95. \u2002Ungprasert P, Srivali N, Kittanamongkolchai W. Risk of incident atrial fibrillation in patients with rheumatoid arthritis: A systematic review and meta-analysis. <i>Int J Rheum Dis<\/i> 2017; 20: 434\u2013441.","DOI":"10.1111\/1756-185X.12820"},{"key":"91","unstructured":"96. \u2002G\u00f6ldeli O, Dursun E, Komsuoglu B. Dispersion of ventricular repolarization: A new marker of ventricular arrhythmias in patients with rheumatoid arthritis. <i>J Rheumatol<\/i> 1998; 25: 447\u2013450."},{"key":"92","doi-asserted-by":"crossref","unstructured":"97. \u2002Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. <i>Rheumatology<\/i> 2003; 42: 292\u2013297.","DOI":"10.1093\/rheumatology\/keg083"},{"key":"93","doi-asserted-by":"crossref","unstructured":"98. \u2002Eisen A, Arnson Y, Dovrish Z, Hadary R, Amital H. Arrhythmias and conduction defects in rheumatological diseases: A comprehensive review. <i>Semin Arthritis Rheum<\/i> 2008; 39: 145\u2013156.","DOI":"10.1016\/j.semarthrit.2008.05.001"},{"key":"94","doi-asserted-by":"crossref","unstructured":"99. \u2002Guler H, Seyfeli E, Sahin G, Duru M, Akgul F, Saglam H, et al. P wave dispersion in patients with rheumatoid arthritis: Its relation with clinical and echocardiographic parameters. <i>Rheumatol Int<\/i> 2007; 27: 813\u2013818.","DOI":"10.1007\/s00296-007-0307-8"},{"key":"95","doi-asserted-by":"crossref","unstructured":"100. \u2002Galarza-Delgado D, Azpiri-L\u00f3pez J, Colunga-Pedraza I, D\u00e1vila-Jim\u00e9nez JA, Abundis-M\u00e1rquez EE, Guill\u00e9n-Lozoya AH, et al. Left atrial dilation is increased in patients with rheumatoid arthritis: A case-control study. <i>Ann Rheum Dis<\/i> 2018; 77: 1351\u20131352.","DOI":"10.1136\/annrheumdis-2018-eular.7098"},{"key":"96","unstructured":"101. \u2002Schwemmer S, Beer P, Scholmerich J, Fleck M, Straub RH. Cardiovascular and pupillary autonomic nervous dysfunction in patients with rheumatoid arthritis: A cross sectional and longitudinal study. <i>Clin Exp Rheumatol<\/i> 2006; 24: 683\u2013689."},{"key":"97","doi-asserted-by":"crossref","unstructured":"102. \u2002Guin A, Chatterjee Adhikari M, Chakraborty S, Sinhamahapatra P, Ghosh A. Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. <i>Semin Arthritis Rheum<\/i> 2013; 43: 48\u201354.","DOI":"10.1016\/j.semarthrit.2012.12.027"},{"key":"98","doi-asserted-by":"crossref","unstructured":"103. \u2002Wen SN, Liu N, Li SN, Salim M, Yan Q, Wu XY, et al. Catheter ablation of atrial fibrillation in patients with rheumatoid arthritis. <i>J Cardiol<\/i> 2015; 66: 320\u2013325.","DOI":"10.1016\/j.jjcc.2014.12.003"},{"key":"99","doi-asserted-by":"crossref","unstructured":"104. \u2002Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. <i>Rheumatology (Oxford)<\/i> 2014; 53: 650\u2013657.","DOI":"10.1093\/rheumatology\/ket387"},{"key":"100","unstructured":"105. \u2002Aksoy H, Okutucu S, Sayin BY, Oto A. Assessment of cardiac arrhythmias in patients with ankylosing spondylitis by signal-averaged P wave duration and P wave dispersion. <i>Eur Rev Med Pharmacol Sci<\/i> 2016; 20: 1123\u20131129."},{"key":"101","doi-asserted-by":"crossref","unstructured":"106. \u2002Yildirir A, Aksoyek S, Calguneri M, Oto A, Kes S. QT dispression as a predictor of arrhythmic events in patients with ankylosing spondylitis. <i>Rheumatology<\/i> 2000; 39: 875\u2013879.","DOI":"10.1093\/rheumatology\/39.8.875"},{"key":"102","doi-asserted-by":"crossref","unstructured":"107. \u2002Moyssakis I, Gialafos E, Vassiliou VA, Boki K, Votteas V, Sfikakis PP, et al. Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. <i>Scand J Rheumatol<\/i> 2009; 38: 216\u2013222.","DOI":"10.1080\/03009740802474672"},{"key":"103","doi-asserted-by":"crossref","unstructured":"108. \u2002Bergfeldt L, Edhag O, Holm G, Norberg R. Platelet aggregating activity in serum from patients with HLA-B27 associated rheumatic and cardiac disorders: A possible link to the proliferative vascular changes. <i>Br Heart J<\/i> 1991; 65: 184\u2013187.","DOI":"10.1136\/hrt.65.4.184"},{"key":"104","doi-asserted-by":"crossref","unstructured":"110. \u2002Toufan M, Pourafkari L, Nader ND. Left ventricular non-compaction in a patient with ankylosing spondylitis. <i>J Cardiovasc Thorac Res<\/i> 2016; 8: 188\u2013189.","DOI":"10.15171\/jcvtr.2016.37"},{"key":"105","doi-asserted-by":"crossref","unstructured":"111. \u2002Miedany YEI. Spondyloarthritis with psoriasis: New insights. <i>J Arthritis<\/i> 2012; 1: 106.","DOI":"10.4172\/2167-7921.1000106"},{"key":"106","doi-asserted-by":"crossref","unstructured":"112. \u2002Ungprasert P, Srivali N, Kittanamongkolchai W. Psoriasis and risk of incident atrial fibrillation: A systematic review and meta-analysis. <i>Indian J Dermatol Venereol Leprol<\/i> 2016; 82: 489\u2013497.","DOI":"10.4103\/0378-6323.186480"},{"key":"107","doi-asserted-by":"crossref","unstructured":"113. \u2002Upala S, Shahnawaz A, Sanguankeo A. Psoriasis increases risk of new-onset atrial fibrillation: A systematic review and meta-analysis of prospective observational studies. <i>J Dermatolog Treat<\/i> 2017; 28: 406\u2013410.","DOI":"10.1080\/09546634.2016.1255703"},{"key":"108","doi-asserted-by":"crossref","unstructured":"114. \u2002Ahlehoff O, Gislason GH, J\u00f8rgensen CH, Lindhardsen J, Charlot M, Olesen JB, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: A Danish nationwide cohort study. <i>Eur Heart J<\/i> 2012; 33: 2054\u20132064.","DOI":"10.1093\/eurheartj\/ehr285"},{"key":"109","doi-asserted-by":"crossref","unstructured":"115. \u2002Markuszeski L, Bissinger A, Janusz I, Narbutt J, Jedrzejowska AS, Zalewska A. Heart rate and arrhythmia in patients with psoriasis vulgaris. <i>Arch Med Res<\/i> 2007; 38: 64\u201369.","DOI":"10.1016\/j.arcmed.2006.08.004"},{"key":"110","doi-asserted-by":"crossref","unstructured":"116. \u2002Simsek H, Sahin M, Akyol A, Akdag S, Ozkol HU, Gumrukcuoglu HA, et al. Increased risk of atrial and ventricular arrhythmia in long-lasting psoriasis patients. <i>ScientificWorldJournal<\/i> 2013; 2013: 901215.","DOI":"10.1155\/2013\/901215"},{"key":"111","doi-asserted-by":"crossref","unstructured":"117. \u2002Tasal A, Guvenc TS, Kul S, Bacaksiz A, Erdogan E, Sonmez O, et al. Atrial conduction abnormalities in patients with psoriasis vulgaris. <i>Kardiol Pol<\/i> 2015; 73: 637\u2013643.","DOI":"10.5603\/KP.a2015.0028"},{"key":"112","doi-asserted-by":"crossref","unstructured":"118. \u2002Lee SH, Chen YC, Chen YJ, Chang SL, Tai CT, Wongcharoen W, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. <i>Life Sci<\/i> 2007; 80: 1806\u20131815.","DOI":"10.1016\/j.lfs.2007.02.029"},{"key":"113","doi-asserted-by":"crossref","unstructured":"119. \u2002Musa H, Kaur K, O\u2019Connell R, Klos M, Guerrero-Serna G, Avula UM, et al. Inhibition of platelet-derived growth factor-AB signaling prevents electromechanical remodeling of adult atrial myocytes that contact myofibroblasts. <i>Heart Rhythm<\/i> 2013; 10: 1044\u20131051.","DOI":"10.1016\/j.hrthm.2013.03.014"},{"key":"114","doi-asserted-by":"crossref","unstructured":"120. \u2002Mastrolonardo M, Picardi A, Alicino D, Bellomo A, Pasquini P. Cardiovascular reactivity to experimental stress in psoriasis: A controlled investigation. <i>Acta Derm Venereol<\/i> 2006; 86: 340\u2013344.","DOI":"10.2340\/00015555-0099"},{"key":"115","unstructured":"121. \u2002Badokin VV, Kotelnikova GP. The heart damage in patients with psoriatic arthritis. <i>Ter Arkh<\/i> 2004; 76: 56\u201361 (in Russian)."},{"key":"116","doi-asserted-by":"crossref","unstructured":"122. \u2002Egeberg A, Khalid U, Gislason GH, Mallbris L, Skov L, Hansen PR. Association between depression and risk of atrial fibrillation and stroke in patients with psoriasis: A Danish nationwide cohort study. <i>Br J Dermatol<\/i> 2015; 173: 471\u2013479.","DOI":"10.1111\/bjd.13778"},{"key":"117","doi-asserted-by":"crossref","unstructured":"123. \u2002Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. <i>J Am Acad Dermatol<\/i> 2014; 70: 168\u2013177.","DOI":"10.1016\/j.jaad.2013.09.020"},{"key":"118","doi-asserted-by":"crossref","unstructured":"124. \u2002Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gu\u00e9rin A, Singh R, et al. The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-\u03b1 inhibitors versus phototherapy: An observational cohort study. <i>J Am Acad Dermatol<\/i> 2018; 79: 60\u201368.","DOI":"10.1016\/j.jaad.2018.02.050"},{"key":"119","doi-asserted-by":"crossref","unstructured":"125. \u2002Mosiewicz J, Pietrzak A, Chodorowska G, Trojnar M, Szepietowski J, Reich K, et al. Rational for statin use in psoriatic patients. <i>Arch Dermatol Res<\/i> 2013; 305: 467\u2013472.","DOI":"10.1007\/s00403-013-1374-1"},{"key":"120","doi-asserted-by":"crossref","unstructured":"126. \u2002Biagi F, Raiteri A, Schiepatti A, Klersy C, Corazza GR. The relationship between child mortality rates and prevalence of celiac disease. <i>J Pediatr Gastroenterol Nutr<\/i> 2018; 66: 289\u2013294.","DOI":"10.1097\/MPG.0000000000001696"},{"key":"121","doi-asserted-by":"crossref","unstructured":"127. \u2002Emilsson L, Smith JG, West J, Melander O, Ludvigsson JF. Increased risk of atrial fibrillation in patients with coeliac disease: A nationwide cohort study. <i>Eur Heart J<\/i> 2011; 32: 2430\u20132437.","DOI":"10.1093\/eurheartj\/ehr167"},{"key":"122","doi-asserted-by":"crossref","unstructured":"128. \u2002Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N, et al. Celiac disease associated with autoimmune myocarditis. <i>Circulation<\/i> 2002; 105: 2611\u20132618.","DOI":"10.1161\/01.CIR.0000017880.86166.87"},{"key":"123","doi-asserted-by":"crossref","unstructured":"129. \u2002Hallert C, Grant C, Grehn S, Gr. nn. C, Hult.n S, Midhagen G, et al. Evidence of poor vitamin status in coeliac patients on a gluten: Free diet for 10 years. <i>Aliment Pharmacol Ther<\/i> 2002; 16: 1333\u20131339.","DOI":"10.1046\/j.1365-2036.2002.01283.x"},{"key":"124","doi-asserted-by":"crossref","unstructured":"130. \u2002Corazza GR, Frisoni M, Filipponi C, Gullo L, Poggi VM, Gasbarrini G. Investigation of QT interval in adult coeliac disease. <i>BMJ<\/i> 1992; 304: 1285.","DOI":"10.1136\/bmj.304.6837.1285"},{"key":"125","doi-asserted-by":"crossref","unstructured":"131. \u2002M\u2019Koma AE. Inflammatory bowel disease: An expanding global health problem. <i>Clin Med Insights Gastroenterol<\/i> 2013; 6: 33\u201347.","DOI":"10.4137\/CGast.S12731"},{"key":"126","doi-asserted-by":"crossref","unstructured":"132. \u2002Kristensen SL, Lindhardsen J, Ahlehoff O, Erichsen R, Lamberts M, Khalid U, et al. Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: A nationwide study. <i>Europace<\/i> 2014; 16: 477\u2013484.","DOI":"10.1093\/europace\/eut312"},{"key":"127","doi-asserted-by":"crossref","unstructured":"133. \u2002Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. <i>Gut<\/i> 1994; 35: 77\u201383.","DOI":"10.1136\/gut.35.1.77"},{"key":"128","doi-asserted-by":"crossref","unstructured":"134. \u2002Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and inter-leukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. <i>Am J Cardiol<\/i> 2005; 95: 764\u2013767.","DOI":"10.1016\/j.amjcard.2004.11.032"},{"key":"129","doi-asserted-by":"crossref","unstructured":"135. \u2002Luckett LR, Gallucci RM. Interleukin-6 (IL-6) modulates migration and matrix metalloproteinase function in dermal fibroblasts from IL-6KO mice. <i>Br J Dermatol<\/i> 2007; 156: 1163\u20131171.","DOI":"10.1111\/j.1365-2133.2007.07867.x"},{"key":"130","doi-asserted-by":"crossref","unstructured":"136. \u2002Pattanshetty DJ, Anna K, Gajulapalli RD, Sappati-Biyyani RR. Inflammatory bowel \u201ccardiac\u201d disease: Point prevalence of atrial fibrillation in inflammatory bowel disease population. <i>Saudi J Gastroenterol<\/i> 2015; 21: 325\u2013329.","DOI":"10.4103\/1319-3767.166208"},{"key":"131","doi-asserted-by":"crossref","unstructured":"137. \u2002Efe TH, Cimen T, Ertem AG, Coskun Y, Bilgin M, Sahan HF, et al. Atrial electromechanical properties in inflammatory bowel disease. <i>Echocardiography<\/i> 2016; 33: 1309\u20131316.","DOI":"10.1111\/echo.13261"},{"key":"132","doi-asserted-by":"crossref","unstructured":"138. \u2002Dogan Y, Soylu A, Eren GA, Poturoglu S, Dolapcioglu C, Sonmez K, et al. Evaluation of QT and P wave dispersion and mean platelet volume among inflammatory bowel disease patients. <i>Int J Med Sci<\/i> 2011; 8: 540\u2013546.","DOI":"10.7150\/ijms.8.540"},{"key":"133","doi-asserted-by":"crossref","unstructured":"139. \u2002Sharma P, Makharia GK, Ahuja V, Dwivedi SN, Deepak KK. Autonomic dysfunctions in patients with inflammatory bowel disease in clinical remission. <i>Dig Dis Sci<\/i> 2009; 54: 853\u2013861.","DOI":"10.1007\/s10620-008-0424-6"},{"key":"134","doi-asserted-by":"crossref","unstructured":"140. \u2002Knorr JP, Moshfeghi M, Sokoloski MC. Ciprofloxacin-induced Q-T interval prolongation. <i>Am J Health Syst Pharm<\/i> 2008; 65: 547\u2013551.","DOI":"10.2146\/ajhp070081"},{"key":"135","doi-asserted-by":"crossref","unstructured":"141. \u2002Riccioni G, Bucciarelli V, Di Ilio E, Scotti L, Aceto A, D\u2019Orazio N, et al. Recurrent atrial fibrillation in a patient with ulcerative colitis treated with azathioprine: Case report and review of the literature. <i>Int J Immunopathol Pharmacol<\/i> 2011; 24: 247\u2013249.","DOI":"10.1177\/039463201102400131"},{"key":"136","doi-asserted-by":"crossref","unstructured":"142. \u2002Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN, et al. Cardiac sarcoidosis. <i>Am Heart J<\/i> 2009; 157: 9\u201321.","DOI":"10.1016\/j.ahj.2008.09.009"},{"key":"137","doi-asserted-by":"crossref","unstructured":"143. \u2002Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harl\u00e9 JR, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. <i>Arthritis Rheumatol<\/i> 2014; 66: 2503\u20132511.","DOI":"10.1002\/art.38731"},{"key":"138","doi-asserted-by":"crossref","unstructured":"144. \u2002Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Mycoardial lesions of progressive systemic sclerosis. A cause of cardiac dysfunction. <i>Circulation<\/i> 1976; 53: 483\u2013490.","DOI":"10.1161\/01.CIR.53.3.483"},{"key":"139","unstructured":"145. \u2002Mitchell AR, Newton JD, Banning AP. Specific heart muscle disorders. <i>In<\/i>: Warrell DA, Cox TM, Firth JD, Dwight J, editors. Oxford textbook of medicine: Cardiovascular disorders. Oxford University Press: Oxford, 2016; 276\u2013280."},{"key":"140","doi-asserted-by":"crossref","unstructured":"146. \u2002Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: A study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Ann Rheum Dis<\/i> 2010; 69: 1809\u20131815.","DOI":"10.1136\/ard.2009.114264"},{"key":"141","doi-asserted-by":"crossref","unstructured":"147. \u2002Lynge TH, Svane J, Pedersen-Bjergaard U, Gislason G, Torp-Pedersen C, Banner J, et al. Sudden cardiac death caused by myocarditis in persons aged 1\u201349 years: A nationwide study of 14 294 deaths in Denmark. <i>Forensic Sci Res<\/i> 2019; 4: 247\u2013256.","DOI":"10.1080\/20961790.2019.1595352"},{"key":"142","unstructured":"148. \u2002Australian Institute of Health and Welfare. Deaths among people with diabetes in Australia 2009\u20132014. https:\/\/www.aihw.gov.au\/getmedia\/c164ec7c-fc66-4991-8e53-62eba274ead4\/aihw-cvd-79.pdf.aspx?inline=true (accessed January 2, 2020)."},{"key":"143","doi-asserted-by":"crossref","unstructured":"149. \u2002Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O, et al. Diabetes, glucose tolerance, and the risk of sudden cardiac death. <i>BMC Cardiovasc Disord<\/i> 2016; 16: 51.","DOI":"10.1186\/s12872-016-0231-5"},{"key":"144","doi-asserted-by":"crossref","unstructured":"150. \u2002Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. <i>Thyroid<\/i> 2012; 22: 661\u2013679.","DOI":"10.1089\/thy.2011.0334"},{"key":"145","doi-asserted-by":"crossref","unstructured":"151. \u2002Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. <i>Arthritis Rheum<\/i> 2011; 63: 1182\u20131189.","DOI":"10.1002\/art.30277"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/5\/84_CJ-19-0705\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T03:19:25Z","timestamp":1587784765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/5\/84_CJ-19-0705\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":145,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-19-0705","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]}}}